Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Clinical trial NCT06937099 · RECRUITING
Trial details
- NCT number
- NCT06937099
- Sponsor
- Eli Lilly and Company
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-26
- Primary completion
- 2028-05-01
- Enrollment
- 290
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.